Albireo pharma, inc. (ALBO)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Sep'10
Assets
Current assets:
Cash and cash equivalents

150,515

131,843

142,666

157,722

150,339

163,885

173,602

183,228

192,916

53,231

57,073

62,598

20,143

29,931

28,684

31,024

33,433

5,120

40,845

44,355

17,753

19,726

24,588

24,480

28,686

35,241

39,781

42,382

27,901

34,278

39,050

43,691

29,844

35,052

38,701

41,999

22,922

Trade receivables

-

-

-

-

-

-

-

-

-

-

11

-

1

-

-

-

-

1,272

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21

21

21

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

60

60

60

60

1,060

1,560

60

60

60

150

Marketable securities, available for sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,001

Income taxes receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

6

6

6

18

34

34

34

34

35

35

35

86

116

Grants receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

227

207

97

26

25

29

284

88

-

-

-

0

-

-

Other receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

9

0

-

-

1

-

11

Prepaid expenses and other current assets

7,818

9,956

5,353

5,310

1,194

3,765

490

610

661

1,054

326

471

553

560

130

283

684

346

262

384

625

895

316

394

610

725

264

688

953

1,116

295

416

627

827

399

497

365

Other receivables

-

-

-

-

2,803

-

2,304

2,406

1,438

726

730

663

640

370

-

-

-

202

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

-

Total current assets

158,333

141,799

148,019

163,032

154,336

167,650

176,396

186,244

195,015

55,011

58,140

63,732

21,337

30,861

28,835

31,328

34,138

6,940

41,107

44,739

18,378

20,621

24,904

25,103

29,509

36,069

40,077

43,173

28,977

35,772

39,536

45,201

32,066

35,974

39,196

42,651

29,565

Property and equipment, net

554

597

633

544

173

187

199

210

172

178

190

155

111

21

-

0

0

34

280

321

338

380

481

604

755

883

1,031

1,157

1,314

1,473

1,552

1,662

1,878

2,059

2,253

2,432

2,998

Intangible assets

-

-

-

-

-

-

-

-

-

-

1,000

150

150

150

34

34

35

-

37

37

38

39

40

41

41

42

43

44

45

45

46

47

48

49

49

50

53

Goodwill

17,260

17,260

17,260

17,260

17,260

17,260

17,260

17,260

17,260

17,260

17,260

18,110

18,110

18,110

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

5,962

5,413

5,578

1,115

1,209

369

396

422

449

775

503

529

594

518

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

7

9

-

Total assets

182,109

165,069

171,490

181,951

172,978

185,466

194,251

204,136

212,896

73,224

77,093

82,676

40,302

49,660

28,869

31,362

34,173

6,974

41,424

45,097

18,754

21,040

25,425

25,748

30,305

36,994

41,151

44,374

30,336

37,290

41,134

46,910

33,992

38,082

41,505

45,142

32,616

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

6,788

4,785

3,185

3,837

2,987

4,352

3,481

3,020

2,248

1,350

1,577

1,329

1,309

972

-

-

-

1,929

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

7,561

13,486

8,459

7,555

6,385

8,165

5,278

4,353

4,497

6,105

4,568

3,825

3,949

7,548

-

-

-

2,576

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Advances from licensees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term debt, current portion

-

-

-

-

-

-

-

-

-

-

1,470

1,928

2,488

3,075

-

-

-

2,514

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants liability

-

-

-

-

-

-

-

-

-

-

-

-

1,202

844

-

-

-

1,163

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

798

653

683

393

569

308

327

541

411

474

315

298

126

269

-

-

-

63

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

150

467

115

-

421

189

346

435

172

374

641

1,788

246

240

312

1,129

285

180

114

151

222

102

1,989

Clinical trial expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

30

-

1

575

399

210

214

132

25

257

181

199

111

2,158

488

427

872

752

763

974

1,362

Payroll and related

-

-

-

-

-

-

-

-

-

-

-

-

-

-

354

344

233

-

863

1,317

986

645

958

991

721

491

1,139

1,064

790

499

1,248

1,113

795

1,337

1,118

954

357

Accounting and legal fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

192

441

269

-

289

308

222

173

131

170

118

160

226

263

239

230

244

287

217

205

191

228

300

Restructuring

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,394

1,404

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Severance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31

96

162

255

286

286

0

141

306

471

643

688

-

-

Severance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

686

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,375

123

143

-

234

115

146

225

141

266

247

173

319

432

130

173

273

382

148

309

204

-

334

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

241

-

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

3

2

-

0

7

3

75

75

97

93

101

73

97

105

103

47

45

Total current liabilities

15,147

18,924

12,327

11,785

9,941

12,825

9,086

7,914

7,156

7,929

7,930

7,380

9,074

12,708

2,071

2,770

2,210

8,282

1,808

2,520

2,102

1,690

1,616

1,964

1,855

3,034

2,441

2,559

1,965

4,282

2,780

2,768

2,714

3,502

3,289

3,232

4,387

Liability related to sale of future royalties

49,407

48,714

53,073

52,224

51,433

49,969

48,461

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liability related to sale of future royalties

-

-

-

-

-

-

-

46,736

45,533

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

255

213

-

37

39

41

42

43

43

21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,866

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,047

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

7

3

-

5

183

302

468

1,014

2,413

3,960

3,535

6,121

9,657

5,226

5,110

7,338

7,182

995

1,141

996

9,717

4,169

Other long-term liabilities

4,121

4,270

4,418

-

-

35

-

-

-

-

-

-

-

-

358

-

-

-

54

-

-

-

0

0

0

0

26

57

122

-

0

0

-

-

142

313

-

Restructuring and other long term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

625

965

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total liabilities

68,675

71,908

69,818

64,264

61,587

62,829

57,584

54,689

52,730

7,971

7,973

7,423

9,095

12,708

2,430

3,402

3,178

15,195

1,867

2,703

2,404

2,158

2,630

4,377

5,815

6,569

8,588

12,273

7,313

9,392

10,118

9,950

3,709

4,643

4,427

13,262

8,556

Convertible preference shares, $0.013 par value per share  0 and 44,945,080 shares authorized at December 31, 2016 and December 31, 2015; 0 and 39,354,000 shares issued and outstanding at December 31, 2016 and December 31, 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

520

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Commitments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

0

0

-

0

0

0

0

0

0

0

0

-

Stockholders' Equity:
Ordinary shares, $0.013 par value per share  0 and 265,650 authorized and issued and outstanding at December 31, 2016 and December 31, 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible preferred stock, $0.01 par value; 50,000,000 shares authorized, 1,909,410 and 0 issued and outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

19

19

-

-

19

-

-

-

-

52

54

54

-

-

-

18

-

18

-

Common stock, $0.01 par value per share - 30,000,000 authorized at March 31, 2020 and December 31, 2019; 14,977,855 and 12,749,443 issued and outstanding at March 31, 2020 and December 31, 2019, respectively

149

127

126

126

120

120

120

120

119

89

91

90

63

63

21

641

641

-

21

622

-

-

231

-

-

-

-

189

142

142

-

-

-

386

-

386

264

Convertible preferred stock, $.01 par value; 50,000,000 shares authorized; 1,950,000 and 1,909,410 issued and outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19

19

-

19

19

19

19

-

-

-

54

54

18

-

18

-

-

Common stock, $.01 par value; 200,000,000 shares authorized; 23,079,543 and 24,620,322 issued and outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

246

235

-

211

211

211

211

-

-

-

142

140

389

-

96

-

-

Additional paid in capital

291,221

245,769

242,638

240,734

217,807

214,694

213,005

211,140

209,830

114,522

113,515

112,549

62,743

61,338

288,469

287,793

287,733

-

287,813

286,817

254,687

252,874

252,104

248,414

248,328

248,066

247,761

246,473

227,809

227,464

226,913

226,980

214,040

212,882

212,310

210,955

188,549

Accumulated other comprehensive income

12,739

6,452

10,573

6,582

6,591

4,293

4,150

4,768

2,195

1,001

817

1,406

1,017

1,496

-

-

-

804

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Accumulated deficit

-190,675

-159,187

-151,665

-129,755

-113,127

-96,470

-80,608

-66,581

-51,978

-50,359

-45,303

-38,792

-32,616

-25,945

-262,051

-260,474

-257,379

-9,595

-248,296

-245,064

-238,602

-

-229,559

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated deficit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

234,246

-

227,273

224,068

217,871

215,428

214,613

204,982

199,762

196,093

190,214

184,164

179,847

175,346

179,479

164,754

Total stockholders' equity

113,434

93,161

101,672

117,687

111,391

122,637

136,667

149,447

160,166

65,253

69,120

75,253

31,207

36,952

26,439

27,960

30,995

-8,741

39,557

42,394

16,350

18,882

22,795

21,371

24,490

30,425

32,563

32,101

23,023

27,898

31,016

36,960

30,283

33,439

37,078

-

24,060

Total stockholders' equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31,880

-

Total liabilities and stockholders' equity

182,109

165,069

171,490

181,951

172,978

185,466

194,251

204,136

212,896

73,224

77,093

82,676

40,302

49,660

28,869

31,362

34,173

6,974

41,424

45,097

18,754

21,040

25,425

25,748

30,305

36,994

41,151

44,374

30,336

37,290

41,134

46,910

33,992

38,082

41,505

45,142

32,616